NCT00796770 is a Phase 1 clinical trial of Dendritic Cell Vaccine in HIV, sponsored by Baylor Research Institute.

Who is sponsoring NCT00796770?

NCT00796770 is sponsored by Baylor Research Institute.

What drugs are being tested in NCT00796770?

Interventions in NCT00796770: Dendritic Cell Vaccine.

Is NCT00796770 still recruiting?

NCT00796770 is currently completed. Last updated 9 June 2017.

Last reviewed 2017-06-09 · How we verify

NCT00796770

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vaccination of HIV-1 Infected Patients With Ex-vivo Generated Interferon-α Dendritic Cells Loaded With HIV-1 Lipopeptides and Activated With Lipopolysaccharide in Addition to Antiretroviral Treatment: Exploratory Phase I Study-(DALIA Trial)

Completed Phase 1 Last updated 9 June 2017

What this trial tests

Phase 1 trial testing Dendritic Cell Vaccine in HIV in 19 participants. Completed in 1 September 2011.

Timeline

1 November 2008

Primary endpoint
1 September 2011

1 September 2011

Quick facts

Lead sponsor	Baylor Research Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	1 November 2008
Primary completion	1 September 2011
Estimated completion	1 September 2011
Sites	1 location across United States

Drugs / interventions tested

Dendritic Cell Vaccine — full drug profile →

Conditions studied

HIV — all drugs for HIV →

Sponsor

Baylor Research Institute

Who can join

18 and older, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the safety of the vaccination schedule at week 24 and the safety of the Analytical Treatment Interruption at week 48 in HIV-1 infected patients.
Time frame: May 2010

Sponsor's own description

The purpose of this study is to determine whether the administration of a dendritic cell vaccine is a safe and effective treatment for HIV-1 patients.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Time-Course Gene Set Analysis for Longitudinal Gene Expression Data.
Hejblum BP, Skinner J, Thiébaut R. · · 2015 · cited 51× · PMID 26111374 · DOI 10.1371/journal.pcbi.1004310
Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.
Flamar AL, Xue Y, Zurawski SM, Montes M, et al · · 2013 · cited 43× · PMID 23615121 · DOI 10.1097/qad.0b013e3283624305
Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.
Cobb A, Roberts LK, Palucka AK, Mead H, et al · · 2011 · cited 33× · PMID 21093448 · DOI 10.1016/j.jim.2010.11.002
Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination.
Surenaud M, Montes M, Lindestam Arlehamn CS, Sette A, et al · · 2019 · cited 26× · PMID 31498845 · DOI 10.1371/journal.ppat.1008011
Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials.
Akbari E, Seyedinkhorasani M, Bolhassani A. · · 2023 · cited 7× · PMID 37156468 · DOI 10.1016/j.bjid.2023.102774
Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.
Jin F, Xie L, Zhang H, Fan X, et al · · 2025 · cited 1× · PMID 41200280 · DOI 10.1002/mco2.70455

Verify or expand the search:

Other trials of Dendritic Cell Vaccine

Trials testing the same drug.

NCT06805656 — Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals · Phase 2 · not yet recruiting
NCT05321940 — Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias · Phase 1 · withdrawn
NCT05767684 — Neoantigen Derived DCs as Cancer Treatment · Phase 1 · unknown
NCT01902771 — Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors · Phase 1 · terminated
NCT01808820 — Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma · Phase 1 · completed

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other Baylor Research Institute trials

Trials by the same sponsor.

NCT07467720 — Study to Evaluate the Clinical Utility of Radiation Exposure Reduction: Multi-site Rampart Guardian Peripheral Trial · NA · not yet recruiting
NCT07547878 — Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) · Phase 4 · not yet recruiting
NCT07460583 — ProActive Athlete Heart Program: Proposal for Cardiac Risk Screening in Former High-Intensity Athletes · NA · not yet recruiting
NCT07096544 — CALM Study: Cardiomems Assisted Lvad Management · NA · not yet recruiting
NCT07220395 — eHealth Literacy Intervention for Spanish Speaking Older Adults in the US · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00796770 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baylor Research Institute
Last refreshed: 9 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00796770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing